246 related articles for article (PubMed ID: 33150452)
1. Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study.
Kramers BJ; Koorevaar IW; De Boer R; Hoorn EJ; Pena MJ; Gansevoort RT; Meijer E;
Nephrol Dial Transplant; 2021 Sep; 36(10):1828-1836. PubMed ID: 33150452
[TBL] [Abstract][Full Text] [Related]
2. Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study.
Schroeder EB; Chonchol M; Shetterly SM; Powers JD; Adams JL; Schmittdiel JA; Nichols GA; O'Connor PJ; Steiner JF
Clin J Am Soc Nephrol; 2018 May; 13(5):727-734. PubMed ID: 29572286
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function.
Edwards C; Hundemer GL; Petrcich W; Canney M; Knoll G; Burns K; Bugeja A; Sood MM
JAMA Netw Open; 2021 Sep; 4(9):e2123365. PubMed ID: 34524440
[TBL] [Abstract][Full Text] [Related]
4. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
Chonchol M; Gitomer B; Isakova T; Cai X; Salusky I; Pereira R; Abebe K; Torres V; Steinman TI; Grantham JJ; Chapman AB; Schrier RW; Wolf M
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1461-1469. PubMed ID: 28705885
[TBL] [Abstract][Full Text] [Related]
6. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
[TBL] [Abstract][Full Text] [Related]
7. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Gansevoort RT; van Gastel MDA; Chapman AB; Blais JD; Czerwiec FS; Higashihara E; Lee J; Ouyang J; Perrone RD; Stade K; Torres VE; Devuyst O;
Kidney Int; 2019 Jul; 96(1):159-169. PubMed ID: 30898339
[TBL] [Abstract][Full Text] [Related]
8. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
Nakajima A; Lu Y; Kawano H; Horie S; Muto S
Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
[TBL] [Abstract][Full Text] [Related]
9. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M
Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863
[TBL] [Abstract][Full Text] [Related]
10. Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease.
Kramers BJ; Koorevaar IW; Drenth JPH; de Fijter JW; Neto AG; Peters DJM; Vart P; Wetzels JF; Zietse R; Gansevoort RT; Meijer E
Kidney Int; 2020 Oct; 98(4):989-998. PubMed ID: 32534051
[TBL] [Abstract][Full Text] [Related]
11. Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort study.
Fitzpatrick JK; Yang J; Ambrosy AP; Cabrera C; Stefansson BV; Greasley PJ; Patel J; Tan TC; Go AS
BMJ Open; 2022 Jan; 12(1):e048755. PubMed ID: 35105612
[TBL] [Abstract][Full Text] [Related]
12. Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD.
Knol MGE; Bais T; Geertsema P; Connelly MA; Bakker SJL; Gansevoort RT; van Gastel MDA;
Nephrol Dial Transplant; 2024 Apr; 39(5):838-847. PubMed ID: 37974030
[TBL] [Abstract][Full Text] [Related]
13. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
Torres VE; Abebe KZ; Schrier RW; Perrone RD; Chapman AB; Yu AS; Braun WE; Steinman TI; Brosnahan G; Hogan MC; Rahbari FF; Grantham JJ; Bae KT; Moore CG; Flessner MF
Kidney Int; 2017 Feb; 91(2):493-500. PubMed ID: 27993381
[TBL] [Abstract][Full Text] [Related]
14. Association of Thiazide Diuretics With Diabetes Progression, Kidney Disease Progression, Cardiovascular Outcomes, and Death Among Patients With Diabetes Who Initiate Statins.
Afify H; Gonzalez-Morales U; Asmar A; Alvarez CA; Mansi IA
Am J Cardiol; 2023 Sep; 203():274-284. PubMed ID: 37516035
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
Geurts F; Xue L; Kramers BJ; Zietse R; Gansevoort RT; Fenton RA; Meijer E; Salih M; Hoorn EJ;
Clin J Am Soc Nephrol; 2023 Nov; 18(11):1426-1434. PubMed ID: 37574650
[TBL] [Abstract][Full Text] [Related]
16. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.
Boertien WE; Meijer E; Li J; Bost JE; Struck J; Flessner MF; Gansevoort RT; Torres VE;
Am J Kidney Dis; 2013 Mar; 61(3):420-9. PubMed ID: 23089511
[TBL] [Abstract][Full Text] [Related]
17. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.
Heida JE; Gansevoort RT; Messchendorp AL; Meijer E; Casteleijn NF; Boertien WE; Zittema D;
Clin J Am Soc Nephrol; 2021 Feb; 16(2):204-212. PubMed ID: 33504546
[TBL] [Abstract][Full Text] [Related]
18. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
[TBL] [Abstract][Full Text] [Related]
19. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.
Brosnahan GM; You Z; Wang W; Gitomer BY; Chonchol M
Curr Hypertens Rev; 2021; 17(3):228-237. PubMed ID: 32807060
[TBL] [Abstract][Full Text] [Related]
20. Urinary renin-angiotensin markers in polycystic kidney disease.
Salih M; Bovée DM; Roksnoer LCW; Casteleijn NF; Bakker SJL; Gansevoort RT; Zietse R; Danser AHJ; Hoorn EJ
Am J Physiol Renal Physiol; 2017 Oct; 313(4):F874-F881. PubMed ID: 28747358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
